NewLink Genetics to Participate in Three Investor Conferences in November
November 09 2016 - 7:00AM
NewLink Genetics Corporation (NASDAQ:NLNK), a biopharmaceutical
company focused on bringing novel immuno-oncology therapies to
patients with cancer, today announced that it will participate in
the Global Mizuho Investor Conference on November 14, the Stifel
2016 Healthcare Conference on November 15 and the Piper Jaffray
28th Annual Healthcare Conference on November 29, all to be held in
New York City.
A live webcast of the presentations, if available, will be on
the Company's website at www.newlinkgenetics.com in the
"Investors & Media" section under "Events and
Presentations."
About NewLink Genetics
Corporation
NewLink Genetics is a biopharmaceutical company at the
forefront of discovering, developing and commercializing novel
immuno-oncology product candidates to improve the lives of patients
with cancer. NewLink Genetics' product candidates are
designed to harness multiple components of the immune system to
combat cancer. For more information, please visit
http://www.newlinkgenetics.com.
Cautionary Note Regarding
Forward-Looking Statements
This press release contains forward-looking statements
of NewLink Genetics that involve substantial risks and
uncertainties. All statements, other than statements of historical
facts, contained in this press release are forward-looking
statements, within the meaning of The Private Securities Litigation
Reform Act of 1995. The words "anticipate," "believe," "estimate,"
"expect," "intend," "may," "plan," "target," "potential," "will,"
"could," "should," "seek" or the negative of these terms or other
similar expressions are intended to identify forward-looking
statements, although not all forward-looking statements contain
these identifying words. These forward-looking statements include
any statements other than statements of historical fact. Actual
results or events could differ materially from the plans,
intentions and expectations disclosed in the forward-looking
statements that NewLink Genetics makes due to a number of
important factors, including those risks discussed in "Risk
Factors" and elsewhere in NewLink Genetics' Annual Report
on Form 10-K for the year ended December 31, 2015 and
other reports filed with the U.S. Securities and Exchange
Commission (SEC). The forward-looking statements in this press
release represent NewLink' Genetics' views as of the date
of this press release. NewLink Genetics anticipates that
subsequent events and developments will cause its views to change.
However, while it may elect to update these forward-looking
statements at some point in the future, it specifically disclaims
any obligation to do so. You should, therefore, not rely on these
forward-looking statements as representing NewLink
Genetics' views as of any date subsequent to the date of this
press release.
Contact:
Jack Henneman
EVP, CFO
(515) 598-2561
Investor@linkp.com
Investor and Media Contacts:
Beth Kurth, VP
LaVoieHealthScience
(617) 374-8800, ext. 106
bkurth@lavoiehealthscience.com
Ben Navon, AVP
LaVoieHealthScience
(617) 374-8800, ext. 108
bnavon@lavoiehealthscience.com
NewLink Genetics (NASDAQ:NLNK)
Historical Stock Chart
From Apr 2024 to May 2024
NewLink Genetics (NASDAQ:NLNK)
Historical Stock Chart
From May 2023 to May 2024